Definium readies 2027 filing for anxiety drug after two positive Phase 3 trials

Definium Therapeutics has cleared a major hurdle for its lead asset. On 9 November 2026, alongside third-quarter results, the company said DT120 ODT succeeded in both Phase 3 trials in generalised anxiety disorder, known as Voyage and Panorama. Hitting the main goal in two separate pivotal studies is the usual basis for a US marketing application.

Definium intends to file a New Drug Application with the US Food and Drug Administration in the first half of 2027. The company also said the agency has granted Breakthrough Therapy status to DT120 ODT in major depressive disorder, a second indication beyond anxiety.

The balance sheet is a notable part of the story. Definium reported roughly $1.05bn in cash and said this should finance operations through 2030. On that basis, the filing and the review period should not depend on near-term fundraising, though the company gave no spending breakdown.

Important details are missing from the information available so far. It contains no efficacy figures, dosing information or safety data from either anxiety trial, so the size of the benefit and the drug's tolerability cannot yet be judged. Definium also reported early Phase 2a results for DT402 in autism spectrum disorder, again without detailed data.

For context, Breakthrough Therapy status is an FDA mechanism meant to speed development and review of treatments for serious conditions, where early evidence points to a substantial improvement over existing options.